{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06319170",
            "orgStudyIdInfo": {
                "id": "TV44749-NPC-10205"
            },
            "organization": {
                "fullName": "Teva Branded Pharmaceutical Products R&D, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder",
            "officialTitle": "A Multi-center, Open-label, Randomized, Parallel-group Trial to Characterize the Pharmacokinetics of Three SC Olanzapine Extended-Release Formulations With Different Release Rates Following Single Administration in Participants With Schizophrenia or Schizoaffective Disorder",
            "therapeuticArea": [
                "Mental Health"
            ],
            "study": "open-label-trial-characterizing-the-pk-of-sc-olanzapine-extended-release-formulations-in-participants-with-schizophrenia-schizoaffective-disorder"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-03-28",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12-11",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-12-11",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-03-13",
            "studyFirstSubmitQcDate": "2024-03-13",
            "studyFirstPostDateStruct": {
                "date": "2024-03-19",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-11",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-12",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Teva Branded Pharmaceutical Products R&D, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The primary objective of the study is to characterize the pharmacokinetics of 3 formulations of olanzapine.\n\nA secondary objective is to evaluate the safety and tolerability of 3 formulations of olanzapine.\n\nAnother secondary objective is to characterize the pharmacokinetics of ZYPREXA.\n\nThe planned duration of the study for each participant is 19 weeks."
        },
        "conditionsModule": {
            "conditions": [
                "Schizophrenia, Schizoaffective Disorder"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 95,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Olanzapine Group A",
                    "type": "EXPERIMENTAL",
                    "description": "Single-dose injection",
                    "interventionNames": [
                        "Drug: Olanzapine Extended Release",
                        "Drug: Olanzapine"
                    ]
                },
                {
                    "label": "Olanzapine Group B",
                    "type": "EXPERIMENTAL",
                    "description": "Single-dose injection",
                    "interventionNames": [
                        "Drug: Olanzapine Extended Release",
                        "Drug: Olanzapine"
                    ]
                },
                {
                    "label": "Olanzapine Group C",
                    "type": "EXPERIMENTAL",
                    "description": "Single-dose injection",
                    "interventionNames": [
                        "Drug: Olanzapine Extended Release",
                        "Drug: Olanzapine"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Olanzapine Extended Release",
                    "description": "Powder and vehicle for injectable suspension",
                    "armGroupLabels": [
                        "Olanzapine Group A",
                        "Olanzapine Group B",
                        "Olanzapine Group C"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Olanzapine",
                    "description": "IntraMuscular Injection",
                    "armGroupLabels": [
                        "Olanzapine Group A",
                        "Olanzapine Group B",
                        "Olanzapine Group C"
                    ],
                    "otherNames": [
                        "ZYPREXA"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Maximum observed plasma drug concentration (Cmax)",
                    "timeFrame": "Randomization to 84 days after randomization"
                },
                {
                    "measure": "Area under the plasma drug concentration-time curve (AUC)",
                    "timeFrame": "Randomization to 84 days after randomization"
                },
                {
                    "measure": "AUC extrapolated to infinity (AUC0-\u221e)",
                    "timeFrame": "Randomization to 84 days after randomization"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Number of participants with at least 1 treatment-emergent adverse event (TEAE)",
                    "timeFrame": "Randomization to 29 days after randomization"
                },
                {
                    "measure": "Number of participants with at least 1 serious adverse event (SAE)",
                    "timeFrame": "Randomization to 29 days after randomization"
                },
                {
                    "measure": "Cmax of ZYPREXA",
                    "timeFrame": "Up to 24 hours after administration of ZYPREXA"
                },
                {
                    "measure": "AUC of ZYPREXA",
                    "timeFrame": "Up to 216 hours after administration of ZYPREXA"
                },
                {
                    "measure": "Apparent plasma terminal elimination rate constant (\u03bbz) of ZYPREXA",
                    "timeFrame": "Up to 216 hours after administration of ZYPREXA"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Body weight \\>50 kg and body mass index (BMI) within the range 18.5 to 38.0 kg/m2, inclusive, at the time of screening\n* Agree to maintain current smoking or nonsmoking status at the time informed consent is obtained and throughout the trial until completion of the end of treatment or early termination (ET) visit (ie, nonsmoking participants must agree not to start smoking and participants who smoke will be excluded if they plan to discontinue smoking during the trial\n* Agree to the inpatient periods required during the trial period\n* Have a current confirmed diagnosis of schizophrenia or schizoaffective disorder according to an evaluation by the Investigator, using the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) (American Psychiatric Association 2013a)\n* Have no ongoing or expected significant life events (eg, pending loss of housing, marital status change, long travel abroad, surgery) that could affect trial outcomes throughout the period of trial participation\n* Women may be included only if they have a negative serum beta human chorionic gonadotropin (HCG) test result at screening; they are surgically sterile (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or postmenopausal\n* Men must be sterile; or if they are potentially of reproductive competence and have sexual relationship with female partners of childbearing potential, they must use, together with their female partners, highly effective birth control methods for the duration of the trial and for 70 days after the last dose administration\n\nNOTE- Additional criteria apply, please contact the investigator for more information\n\nExclusion Criteria:\n\n* Presence or have a history of clinically significant diseases of the renal, hepatic, gastrointestinal, cardiovascular, or musculoskeletal system, or presence or history of clinically significant immunological, endocrine, or metabolic diseases, neurological or psychiatric disorder(s) (other than schizophrenia)\n* History or known risk of narrow-angle glaucoma\n* Uncontrolled diabetes\n* Major trauma or surgery in the 2 months before screening\n* History of malignancy or treatment of malignancy in the last 5 years, excluding resected basal cell or squamous cell carcinoma of the skin\n* The participant is a pregnant or lactating woman or plans to become pregnant during the trial or within 70 days after the last dose administration\n* Personal or family history of arrhythmia, sudden unexplained death at a young age (before 40 years) in a first-degree relative, long QT syndrome, personal history of syncope, or history of uncontrolled high blood pressure\n\nNOTE- Additional criteria apply, please contact the investigator for more information",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "64 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Teva U.S. Medical Information",
                    "role": "CONTACT",
                    "phone": "1-888-483-8279",
                    "email": "USMedInfo@tevapharm.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Teva Medical Expert, MD",
                    "affiliation": "Teva Branded Pharmaceutical Products R&D, Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Teva Investigational Site 15730",
                    "status": "RECRUITING",
                    "city": "Los Alamitos",
                    "state": "California",
                    "zip": "90720",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.80307,
                        "lon": -118.07256
                    }
                },
                {
                    "facility": "Teva Investigational Site 15727",
                    "status": "RECRUITING",
                    "city": "Hollywood",
                    "state": "Florida",
                    "zip": "33024",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 26.0112,
                        "lon": -80.14949
                    }
                },
                {
                    "facility": "Teva Investigational Site 15729",
                    "status": "RECRUITING",
                    "city": "Atlanta",
                    "state": "Georgia",
                    "zip": "30331",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.749,
                        "lon": -84.38798
                    }
                },
                {
                    "facility": "Teva Investigational Site 15728",
                    "status": "RECRUITING",
                    "city": "Decatur",
                    "state": "Georgia",
                    "zip": "30030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.77483,
                        "lon": -84.29631
                    }
                },
                {
                    "facility": "Teva Investigational Site 15726",
                    "status": "RECRUITING",
                    "city": "Marlton",
                    "state": "New Jersey",
                    "zip": "08053",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.89122,
                        "lon": -74.92183
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Qualified researchers may request access to patient level data and related study documents including the study protocol and the statistical analysis plan. Requests will be reviewed for scientific merit, product approval status, and conflicts of interest. Patient level data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Please visit www.clinicalstudydatarequest.com to make your request."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000012559",
                    "term": "Schizophrenia"
                },
                {
                    "id": "D000011618",
                    "term": "Psychotic Disorders"
                }
            ],
            "ancestors": [
                {
                    "id": "D000019967",
                    "term": "Schizophrenia Spectrum and Other Psychotic Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M15376",
                    "name": "Schizophrenia",
                    "asFound": "Schizophrenia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "asFound": "Schizoaffective Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21838",
                    "name": "Schizophrenia Spectrum and Other Psychotic Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000077152",
                    "term": "Olanzapine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000932",
                    "term": "Antiemetics"
                },
                {
                    "id": "D000001337",
                    "term": "Autonomic Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000005765",
                    "term": "Gastrointestinal Agents"
                },
                {
                    "id": "D000014150",
                    "term": "Antipsychotic Agents"
                },
                {
                    "id": "D000014149",
                    "term": "Tranquilizing Agents"
                },
                {
                    "id": "D000002492",
                    "term": "Central Nervous System Depressants"
                },
                {
                    "id": "D000011619",
                    "term": "Psychotropic Drugs"
                },
                {
                    "id": "D000017367",
                    "term": "Selective Serotonin Reuptake Inhibitors"
                },
                {
                    "id": "D000014179",
                    "term": "Neurotransmitter Uptake Inhibitors"
                },
                {
                    "id": "D000049990",
                    "term": "Membrane Transport Modulators"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000018490",
                    "term": "Serotonin Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M1675",
                    "name": "Olanzapine",
                    "asFound": "Field",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4251",
                    "name": "Antiemetics",
                    "relevance": "LOW"
                },
                {
                    "id": "M8881",
                    "name": "Gastrointestinal Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M16904",
                    "name": "Antipsychotic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M14474",
                    "name": "Psychotropic Drugs",
                    "relevance": "LOW"
                },
                {
                    "id": "M15512",
                    "name": "Serotonin",
                    "relevance": "LOW"
                },
                {
                    "id": "M19649",
                    "name": "Selective Serotonin Reuptake Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "AnEm",
                    "name": "Antiemetics"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "PsychDr",
                    "name": "Psychotropic Drugs"
                },
                {
                    "abbrev": "Gast",
                    "name": "Gastrointestinal Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}